Zepbound
Product
by Eli Lilly and Company
Zepbound is a prescription injectable medicine containing tirzepatide, used with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight with weight-related medical problems. It is also indicated for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
11 episodes featuring Zepbound
WSJ What’s News
Flight emergency exposes risks behind markets’ calm
The episode connects a dramatic aviation crisis with unresolved questions about central-bank oversight, market concentration, inflation and drug-development tradeoffs.
Sep 30, 2026 · 10 min
The Indicator from Planet Money
Rising costs squeeze renters, insurers, and employers
The episode connects housing strain, ACA coverage losses, and GLP-1 costs as separate pressures converging on households and institutions.
Sep 25, 2026 · 9 min
WSJ What’s News
Trump-Xi summit carries weight beyond concrete deals
The episode connects a symbolically charged U.S.-China meeting with war, alliances, tradeoffs for consumers, and shifting investment priorities.
Sep 23, 2026 · 13 min
WSJ's Take On the Week
Biotech’s rally tests the promise of cancer breakthroughs
Investors must decide whether excitement around cancer vaccines, AI and new drug platforms reflects durable growth or inflated valuations.
Sep 13, 2026 · 32 min
unPAUSED with Dr. Mary Claire Haver
Testosterone enters the menopause conversation
The episode examines what women’s testosterone may do, where evidence remains thin, and how dosing and monitoring shape treatment risk.
Sep 1, 2026 · 1h 13m
The Thyroid (and Hormone) Fixer Podcast: Thyropause, Menopause, Metabolism and How to Fix It
GLP-1 drugs may reshape gut health beyond weight loss
GLP-1 medications could influence inflammation, the intestinal barrier, microbiome, bile acids, and gut-brain signaling, but individual responses and evidence remain unsettled.
Aug 21, 2026 · 46 min
All the Wrong Moves: How America Made Trump
Scaramucci turns public failure into a case for humility
The conversation examines whether resilience comes from confidence alone or from the harder work of self-awareness, vulnerability, and self-forgiveness.
Aug 14, 2026 · 52 min
Louder with Crowder
Crowder makes debate and SPLC allegations the episode’s central test
The episode links media controversy, political hypocrisy, and disputed allegations to a broader argument about evidence, credibility, and public accountability.
Aug 13, 2026 · 1h 1m
The Shawn Ryan Show
Koniver challenges medicine’s shortcuts with personalized longevity care
The conversation tests where individualized health optimization can offer useful alternatives—and where emerging therapies remain uncertain, experimental, or overpromoted.
Aug 13, 2026 · 2h 20m
The Dr. Hyman Show
GLP-1 treatment works best beyond the scale
As GLP-1 use expands, the episode examines how dosing, monitoring, nutrition, and strength training shape its benefits and risks.
Aug 12, 2026 · 1h 17m
We're Out of Time
Addiction can outlast pleasure when cues keep wanting alive
Separating dopamine-driven wanting from pleasure clarifies why relapse can persist after enjoyment fades and points toward more targeted recovery strategies.
Aug 4, 2026 · 1h 1m